StemCell Therapy

ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis, the company pioneering the use of fish skin and fatty acids for tissue regeneration and protection, is donating its Kerecis Omega3 Burn product for burn victims of the fires in California, Oregon and Washington. Qualified medical personnel wanting to take advantage of this offer should contact wildfires@kerecis.com.

These horrific fires are having a devastating effect on human lives and habitat, said G. Fertram Sigurjonsson, founder and CEO of Kerecis. We want to help those who have been burned to heal as quickly and easily as possible. We encourage medical professionals to contact us to get a supply of Kerecis Omega3 Burn for their patients.

About Kerecis Omega3 Burn

Kerecis Omega3 Burn is intact fish skin that, when grafted onto damaged human tissue, recruits the bodys own cells and ultimately is converted into living tissue. Because no disease-transfer risk exists between cold-water fish and humans, the Kerecis fish skin is only gently processed and retains its similarity to human skin, making it an ideal skin substitute. The fish skin contains Omega3 fatty acids and multiple proteins that help the product to become incorporated into the body quickly, while providing a much-needed bacterial barrier to protect the wound bed. Clinical studies have found that the Kerecis products heal wounds faster than competitive products, so patients can be ready for additional tissue building and/or move directly to split-thickness skin grafting in record time. Kerecis Omega3 Burn is available for the treatment of humans as well as for animals.

About Kerecis

Kerecis is pioneering the use of fish skin and fatty acids in the globally expanding cellular- therapy and regenerative-medicine market. The Kerecis fatty-acid-rich intact fish skin protects the bodys tissues and enables the body to regenerate tissues. The Kerecis sprayable fatty-acid topical and oral formulations protect the body from bacterial and viral infections.

The Kerecis products, which are based on fish skin and fatty acids, are currently being used to regenerate tissue in diabetic and trauma wounds (including burns), and for infection control. Kerecis is also developing products for areas such as oral surgery, plastic surgery and neurological applications.

The companys mission is to extend human life by supporting the bodys own ability to regenerate, and its vision is to become the world leader in tissue regeneration by sustainably harnessing natures own remedies. For more information, visit http://www.kerecis.com

Read this article:
Kerecis to Donate its FDA-Approved Fish Skin Treatment for Burn Victims of West Coast Fires - Business Wire

TOKYO--(BUSINESS WIRE)--SanBio Co., Ltd. (headquarters: Chuo-ku, Tokyo, Representative Director and President: Keita Mori, hereafter SanBio) hereby announces that it has obtained new analytical results from the Phase 2b clinical trial (the trial) of SB623 for the treatment of chronic motor deficit resulting from ischemic stroke the SanBio Group (SanBio Co., Ltd. and its subsidiary SanBio, Inc.) conducted in the US. It also announces that based on the newly obtained results, it has updated its development plans, including in regard to late-stage clinical trials for the ischemic stroke and hemorrhagic stroke programs of SB623 in Japan.

The trial evaluated efficacy and safety of SB623 in 163 patients suffering from chronic motor dysfunction from ischemic stroke. On January 29, 2019, SanBio announced that the trial did not meet its primary endpoint, as it failed to demonstrate statistical significance in the difference in the proportion of patients whose Fugl-Meyer Motor Scale (FMMS) score improved by 10 or more points from the baseline (primary endpoint) between the treatment group that received SB623 and the control group. Since then, the SanBio Group had continued to work on additional analysis of the trial data, and results of the additional analysis are as follows.

In conducting the additional analysis, from the perspective of minimal clinically important difference (MCID, or the minimal change in scores or other metrics that could be interpreted to mean the change in a patient is clinically meaningful) and based on the results of the Phase 2 clinical trial of SB623 for the treatment of chronic motor deficit from traumatic brain injury (TBI; STEMTRA trial), the company reevaluated trial data using composite FMMS. Of the total 163 patients enrolled in the trial, the company specifically looked at 77 patients who had infarct areas smaller than a certain size (47% of all patients enrolled in this trial). The SanBio Group evaluated the proportion of patients that met one or more of the following FMMS score improvement criteria 24 weeks after treatment: 6-point improvement on FMMS score for upper extremity, 4-point improvement on FMMS score for lower extremity, and 9-point improvement on FMMS total score (all from the baseline). Of the 51 patients in the treatment group that received SB623, improvement was seen in 49%, versus in 19% of 26 patients in the control group that received sham surgery, the difference between the two groups being statistically significant (p-value of 0.02). SanBio Group thinks that even compared to the primary endpointthe proportion of patients whose FMMS score improved by 10 or more points over the baseline six months after treatmentthe endpoint using composite FMMS can adequately explain clinical significance of the treatment efficacy. Details of the additional analysis results will be announced at the financial results briefing for institutional investors and the media held on September 15, 2020. The briefing video will be made available to the public on our website on the 16th of September or thereafter.

Based on the above results, the SanBio Group has begun preparations for the next late-stage clinical trials in the ischemic stroke and hemorrhagic stroke programs of SB623. 2021. Specific designs of the clinical trials and the contents of development for those two programs will be announced promptly upon being finalized. To maximize the value of SB623 at an early stage by selecting areas to focus the Groups management resources on, the SanBio Group plans to prioritize the development of the ischemic stroke and hemorrhagic stroke programs in Japan at the same time as it prepares to file for approval of SB623 for the treatment of chronic motor deficit resulting from TBI in Japan by the end of the current fiscal year (ending January 2021). The Group, however, postponed the global Phase 3 clinical trial for the TBI program of SB623 it had planned to commence this fiscal year to the next or subsequent fiscal years.

Many patients suffering from the chronic effects of ischemic stroke are said to be regularly taking drugs to prevent recurrence. However, because there is no drug that can fundamentally cure motor dysfunction, there is high unmet need for therapeutic drugs to restore motor functions for patients in the chronic phase of stroke. The SanBio Group aims to contribute to improving the lives of these patients, as well as of their family members, suffering from motor impairment and difficulties it causes in carrying out their daily lives through SB623.

About SB623

SB623 is an allogeneic mesenchymal stem cell produced by modifying and culturing bone marrow derived from healthy donors. Implantation of SB623 cells into nerve tissues is expected to promote regeneration of damaged nerve cells. Because SB623 is made from allogeneic cells, large-scale production is possible and there is no need for complex cell processing required for treatments using autologous cells, e.g., cell preparation for each patient at medical institutions. Hence, pharmaceutical products made from allogeneic cells, such as SB623, can be provided to many patients in uniform quality.

About SanBio Co., Ltd. and SanBio, Inc.

SanBio Group is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. The Companys propriety regenerative cell medicine product, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and ischemic stroke. The Company is headquartered in Tokyo, Japan and Mountain View, California, and additional information about SanBio Group is available at https://sanbio.com.

Here is the original post:
Additional Analytical Results of the US-Based Phase 2b Clinical Trial of Regenerative Cell Medicine SB623 for the Treatment of Chronic Motor Deficit...

VANCOUVER, B.C., Sept. 14, 2020 /PRNewswire/ -- The Global Femtech Marketis expected to reach USD 60.01 Billion by 2027, according to a new report by Emergen Research. Demand for the femtech industry is motivated mainly by the growing burden of both chronic and infectious diseases among the world's female population. An increase in the number of health problems relating to women would stimulate competition for technologically innovative healthcare solutions. Growing women's emphasis on reproductive health and sexual empowerment in developing economies would further encourage development in the industry.

Increasing awareness among women of the detection and management of early illness as part of the patient care program would improve the market outlook. Various efforts by government and other agencies in developing countries to raise awareness of women's health would accelerate the development of the industry. Furthermore, an increasing tendency towards daily preventive care check-ups, as well as the advancement of user-friendly technology to track individual health problems, may prove beneficial to the developments in the women's health industry.

While more and more people today choose to be more transparent about their health concerns and treatment, in some of the lesser developed regions, women's health issues remain stigmatized. For these places, Femtech applications are likely to be favored because the scanning is less invasive and more secure. Increasing population growth is related to being one of the main factors behind the case.

Request free sample of this research report at: https://www.emergenresearch.com/request-sample/37

Key Highlights From The Report

Read more at: https://www.emergenresearch.com/industry-report/femtech-market

For the purpose of this report, Emergen Research has segmented into the Global Femtech Market on the basis of type, end-use, application, and region:

Type Outlook (Revenue: USD Billion; 2017-2027)

End Use Outlook (Revenue: USD Billion; 2017-2027)

Application Outlook (Revenue: USD Billion; 2017-2027)

Regional Outlook (Revenue, USD Billion; 2017-2027)

Find more research reports on healthcare and pharmaceuticals industry, by Emergen Research:

Regenerative Medicine MarketRegenerative Medicine Market By Product (Tools, Therapeutics), By Therapeutic Category (Musculoskeletal, Dermatology, Immunology & Inflammation, Cardiovascular), and By Applications (Wound Care, Musculoskeletal Disorders, Ocular Disorders), Forecasts to 2027

Next-Generation Sequencing MarketNext-Generation Sequencing Market by Technology (Whole Exome, Whole Genome, Others), By Workflow (Sequencing, Pre-Sequencing, Others), By Application (Consumer Genomics, HLA Typing, Others) and By End-Use (Academic, Clinical, Others), Forecasts to 2027

RFID in Healthcare MarketBy Product (Tags, Systems & Software) and By Application (Asset Tracking, Patient Tracking, Pharmaceutical Tracking, Blood Tracking, Others), Forecasts to 2027

Non-Invasive Prenatal Testing MarketBy Method, By End-Use, By Application, By Region, Forecasts to 2017-2027

Viral Vector and Plasmid Manufacturing MarketBy Vector Type (Retrovirus, Adenovirus, Others), By Workflow (Upstream, Downstream), By Disease (Cancer, Genetic Disorders, Others), By Application (Gene Therapy, Retailers) and By End-User, Forecasts to 2027

Interoperability Solutions in Healthcare MarketBy Level (Foundational, Structural, Semantic), By Product Type (Services, Solutions), and By Application (Diagnostics, Treatments, Others), Forecasts to 2027

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

With market-leading insights and an in-depth understanding of leading and niche technologies, our solutions address the most pertinent questions for your business needs. A major technological shift has been witnessed towards creating a 'Circular Economy,' fuelled by factors, such as the increased adoption of bio-based materials, along with other methods for achieving carbon neutrality. We are conversant in technologies, viz., Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), Robotic Process Automation (RPA), Smart Manufacturing, Internet of Things (IoT), Big Data Analytics, Machine learning, Nanotechnology, Edge Computing, Blockchain Technology, Cloud Computing, Vehicle Electrification, Advanced Maintenance Analytics, and Predictive Maintenance, among other prevalent and emergent technologies.

Contact Us:Eric LeeCorporate Sales SpecialistEmergen Research | Web: https://www.emergenresearch.comE-mail: [emailprotected]

Read full Press Release at :https://www.emergenresearch.com/press-release/global-femtech-market

SOURCE Emergen Research

Read the original here:
Femtech Market to Reach USD 60.01 Billion By 2027 | CAGR of 15.6%: Emergen Research - PRNewswire

"On behalf of our entire board of directors, we wholeheartedly welcome Terry to his new role as President and CEO of Vizgen," said Dr. David R. Walt, Cofounder of Vizgen; Hansjrg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School; Professor of Pathology, Brigham and Women's Hospital; Core Faculty, Wyss Institute for Bioinspired Engineering, Harvard University; HHMI Professor. "Terry's technical savvy combined with his demonstrated business acumen in building out product and service offerings on a global scale will benefit Vizgen as the Company enters the next phase of commercial development."

Prior to joiningVizgen, Terry was President of Akoya Biosciences, a post he assumed after an acquisition from PerkinElmer where he served as General Manager, Quantitative Pathology Solutions. Previously, he held several executive positions at global biopharma and diagnostic companies including Roche, Hologic, and Bristol-Myers Squibb, and has extensive experience in launching innovative technologies in new markets. He holds an MBA from the University of Chicago Booth School of Business, an MS in Microbiology from Virginia Tech, and dual BS degrees in Molecular Genetics and Psychology from The Ohio State University.

"I'm excited to take the helm at Vizgen to work together with an incredibly talented team of scientists and innovators to bring an unsurpassed spatial profiling technology to market," said Mr. Lo. "Gene expression with spatial context has now become the new research frontier in unlocking core biological questions, and Vizgen's technology is regarded as a premier solution to gain insight into the molecular underpinnings of health, the progression to disease, and the development of new therapies and vaccines."

Vizgen's MERFISHtechnology was developed in the laboratory of Dr. Xiaowei Zhuang, a Howard Hughes Medical Institute Investigator and David B. Arnold, Jr. Professor of Science at Harvard University. Dr. Zhuang and Dr. Jeffrey Moffitt, a former postdoctoral fellow in Dr. Zhuang's lab andnow an Assistant Professor at the Program in Cellular and Molecular Medicine at Boston Children's Hospital and the Department of Microbiology at Harvard Medical School, are also cofounders of Vizgen. MERFISH enables spatially resolved, single-cell genomic profiling at extremely high levels of throughput and accuracy. The novel technology is used as a tool for several Human Cell Atlasprojects and was named a "Technology to Watch" by Nature for mapping the transcriptome.

Vizgen launched in January 2020 with a $14M Series A Financing led by ARCH Venture Partners and Northpond Ventures. Last month the Company announced an early release program for its spatial genomics platformto provide scientific investigators an opportunity to gain access to the proprietary technology to accelerate their research. Vizgen's technology is already being employed by world-leading academic research institutions including the Broad Institute of MIT and Harvard and The Rockefeller University.

For more information email: [emailprotected]

About Vizgen Vizgen is developing the next generation of spatially resolved genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERFISH provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. For more information, go towww.vizgen.com, connect on social media

@Twitter,@LinkedInandFacebook, and join the MERFISH Group at: https://bit.ly/merfishgroup.

SOURCE Vizgen

See original here:
Vizgen Taps Akoya Biosciences Executive Terry Lo As New President and CEO - PRNewswire

Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer

Experienced biotech executive to lead the next phase of growth

14 September 2020

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (Silence or the Company), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces the appointment of Mark Rothera as President and Chief Executive Officer (CEO) and Board member, effective immediately. Iain Ross, who has been Executive Chairman since December 2019, has today assumed his previous position of Non-Executive Chairman.

Mr. Rothera brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of commercial and operational leadership, including driving the successful build of multiple biotech companies, predominantly in the field of rare or specialty diseases. Prior to joining Silence, Mr. Rothera served as CEO of Orchard Therapeutics (Orchard), where he oversaw its transformation from a small U.K.-based, privately held company with two clinical-stage programmes into a leading gene therapy company with seven clinical-stage programmes and fully integrated capabilities. Under his leadership, Orchard completed an initial public offering of American Depositary Shares on the Nasdaq Global Market and during his tenure that company secured more than $600 million in financing and grew from a market capitalization of $250 million to more than $1.7 billion at its peak.

Prior to Orchard, Mr. Rothera served as Chief Commercial Officer of PTC Therapeutics (PTC), where he helped transition that company from a privately held R&D biotechnology company to a publicly traded, commercial-stage company with a global footprint, including the successful launch of two rare disease therapies. He also previously served as Global President of Aegerion Pharmaceuticals Inc. and Vice President and General Manager of commercial operations at Shire Human Genetic Therapies for Europe, Middle East and Africa. Mr. Rothera received an M.A. in Natural Sciences from Cambridge University and an M.B.A. from the European Institute for Business Administration (INSEAD).

Based out of Silences New York City office, Mr. Rothera will lead the continued global expansion of the Company. His appointment follows the completion of Silences Nasdaq listing on 8 September 2020 and aligns with the strategy of increasing the Companys presence in the United States.

Iain Ross, Chairman of Silence Therapeutics plc, said: "On behalf of the Silence Board and the entire Silence team, I welcome Mark to the Company. Following a thorough search, Marks appointment reflects his proven leadership skills and strong track record in growing successful biotechnology companies and building shareholder value. I believe he will now provide the leadership necessary to grow Silence into a leading international biotechnology company built upon our innovative siRNA technology platform, proprietary product pipeline and validating industry partnerships.

On a personal note, and on behalf of the Board, I would like to thank the management team and staff at Silence for their support, hard work and tremendous resilience during the current COVID-19 pandemic and over the past nine months whilst I have been Executive Chairman. The Company has made great strides during this period, and is now in a strong position, both operationally and financially, and ready for Mark to take the helm.

Mark Rothera, President and CEO of Silence Therapeutics plc, added: It is an honour to take the role of leading Silence at this time in the Companys history. I believe the Company is poised to capitalise on its important siRNA technology platform, pipeline and research capabilities built over 18 years, and position itself as a leader in the RNAi field. The Company has made great strides under Iains leadership and I look forward to working with the Board, the management team and Silence employees to build upon this momentum.

Director disclosures

The following information is being disclosed pursuantto Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Mark Rothera

Full name and age: Mark Andrew Rothera (aged 58)

Current Directorships or Partnerships:Genpharm

Previous Directorships or Partnerships in the last 5 years:Orchard Therapeutics plcPTC Therapeutics International LimitedAlliance for Regenerative Medicine

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

Enquiries:

About Silence TherapeuticsSilence Therapeutics is developing a new generation of medicines by harnessing the bodys natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silences proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silences wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500 in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

The person who arranged for the release of this announcement on behalf of the Company was Rob Quinn, Chief Financial Officer.

Forward-Looking StatementsCertain statements made in this announcement are forward-looking statements, including with respect to the Companys clinical and commercial prospects. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

View post:
Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer - GlobeNewswire

Daniel Dennett has inspired many people, but perhaps none more than his former student Jeff Stibel, A95, an entrepreneur and brain scientist. Now Stibel is ensuring that the influential philosophers legacy will continue at Tufts, with a generous gift to create a consortium at the university focused on cognitive and brain science.

Stibels gift will launch the Stibel Dennett Consortium for Brain and Cognitive Science, which will bring together important research and teaching in the field. The consortium will cross university departments and schools, including psychology, biology, philosophy, education, engineering, and medicine, and will serve students, faculty, alumni, and the wider community.

I was inspired to create a new consortium at Tufts that will serve as a center of gravity, to explore important and groundbreaking cognitive and brain science issues through teaching and research, said Stibel, who is the author of two books and a USA Today column on the workings of the mind.

With his fellow partners Stibel has also given to the university BrainGate, Inc., a company that holds intellectual property enabling technologies to read and translate brain signals through a computer interface. The brain's motor cortex sends out electrical pulses that can be recorded by this technology and decoded into motor commands. In the future, the companys technology could help people with spinal injuries or locked-in syndrome control devices, such as a robotic arm or an exoskeleton that would allow a paralyzed person to walk.

The donation of BrainGate, Inc., combined with Stibels support for faculty, promises to spur new research at the university. Stibels gift includes funds to endow two professorships in the School of Arts and Sciences. Gina Kuperberg has been appointed the inaugural Dennett Stibel Professor of Cognitive Science, and Stephanie Badde has been recruited to the faculty as the Stibel Family Assistant Professor of Brain and Cognitive Science.

Kuperberg and Badde plan to build upon the BrainGate technology, exploring a deeper understanding of how the brain processes language as well as how the brain gathers information from our senses and tells our body how to move. Other faculty at Tufts also plan to explore research opportunities related to the BrainGate intellectual property.

What Jeff Stibel has given us is priceless, said James Glaser, dean of the School of Arts and Sciences. The two professorships have enabled us to recognize the excellence of Gina Kuperberg, an important cognitive science faculty member, and to recruit a talented new colleague to the program. And the gift of BrainGate, Inc., will help solidify Tufts international reputation as a locus of excellence in cognitive science.

In just one of its potential applications, the Stibel gift may lead to a deeper understanding of the very nature of human memory, said Michael Levin, A92, the Vannevar Bush Professor of Biology and director of the Allen Discovery Center at Tufts . Levin studies regenerative biologythe process of replacing or "regenerating" human or animal cells, tissues, or organs to restore or establish normal function.

Advances in regenerative medicine depend on understanding electrical anatomical memory, which is like memory in the brain. BrainGates technology could offer key insights into how cells communicate to signal growth, adaptation to trauma, or even the storage of memories.

Using the technology to interpret the communication between cells, we could find out how memories are stored and encoded in tissue, and learn to decode them, Levin said. We also could learn how memories can survive remodeling of the tissue, how memories can be moved or copied, and how memories can belong to a unified self. Levin is currently collaborating with Dennett on research and a publication related to cellular memory and cognition

Tufts will launch the Stibel Dennett Consortium in the fall, through an online event for the Tufts community with other programming to follow.

Angela Nelson can be reached at angela.nelson@tufts.edu.

Stephanie Badde, Stibel Family Assistant Professor of Brain and Cognitive Science: We think our senses give us a good impression of the physical reality around us, but that's just not true. The information were getting is actually very spottyit's as if were wearing blurry glasses with a small hole in the middle. The brain performs a lot of work to take in this input and give us the impression we have. My research asks, How does the brain do this miracle?

With the BrainGate patents, we hope to find out more about how movements and sensory information are connected in the brain, and how this might be leveraged so that people can regain the sense of touch and sense of body posture where theyve lost them.

Gina Kuperberg, Dennett Stibel Professor of Cognitive Science: We take it for granted that as we talk to one another, we are literally transferring thoughts from one mind to another. Language is what enables humans to communicate, and ultimately, language is a code. My research program is aimed at understanding this code. We're trying to figure out not only where, when, and how the brain uses language to communicate, but also the nature of the neural code itself.

The whole idea of decoding brain activity is so important, not only medically for people in the future, but for understanding the nature of the human brain and thought. And were really on the cutting edge of being able to do that, particularly now with the BrainGate intellectual property.

Go here to read the rest:
Getting Smarter About the Mind | Tufts Now - Tufts Now

8/24, StemoniX Inc.-Cancer Genetics Inc." Cancer Genetics and StemoniX have launched a joint proof-of-concept program to assess central nervous system (CNS) safety and toxicity of novel compounds.

8/25, Altivon LP-ConvergeOne: ConvergeOne, an IT-services provider of collaboration and digital infrastructure solutions, has acquired Altivon, a contact center solutions provider.

8/25, Emerson Resources Inc.-Pace Analytical Services: Pace Analytical Services has acquired Emerson Resources, a pharmaceutical contract development and manufacturing organization specializing in dosage form development and clinical trial material manufacturing.

8/26, Reardon Office Equipment-Loffler Cos. Inc.: Loffler Cos. has acquired Reardon Office Equipment to expand its market in North Dakota and northern Minnesota.

8/27, Collagen Solutions PLC-Rosens Diversified Inc.: Rosens Diversified, a food-production, agrochemical and distribution company, will acquire Collagen Solutions, a developer of medical-grade collagen, tissues and related devices and components for use in regenerative medicine, tissue engineering and research.

8/27, Open Systems International-Emerson Electric Co.: Emerson Electric will acquire Open Systems International, an operations technology software provider, for $1.6 billion.

8/28, Bluestem Brands Inc.-BLST Operating Co. LLC: BLST Operating Co., a privately held multibrand e-retailer, has acquired multibrand e-retailer Bluestem Brands.

Continued here:
Minnesota mergers and acquisitions - Minneapolis Star Tribune

Rheumatoid Arthritis Stem Cell Therapy Market: Outlook

Regenerative medicine has made extensive advancements over the years to cure the populace of certain disorders or diseases. Stem cell therapy is a category of regenerative medicine that has gained considerable traction over the years as an efficient treatment option for a plethora of disorders including rheumatoid arthritis. Therefore, the global rheumatoid arthritis stem cell therapy market will bank on the efficacy of bringing rheumatoid arthritis in control across the forecast period of 2020-2030.

Based on treatment type, the global rheumatoid arthritis stem cell therapy market can be classified into bone marrow transplant, Allogeneic Mesenchymal stem cells, and adipose tissue stem cells. On the basis of the distribution channel, the rheumatoid arthritis stem cell therapy market can be segmented into ambulatory surgical centers, specialty clinics, and hospitals.

Request a sampleto get extensive insights into the Rheumatoid Arthritis Stem Cell Therapy Market

This upcoming research report by Transparency Market Research on the rheumatoid arthritis stem cell therapy market enlightens the stakeholder about numerous aspects such as competitive landscape, geographical analysis, current and upcoming trends, and others. The report also sheds light on the pain points and helps the stakeholder in preparing efficient business strategies to overcome them.

The report also covers the changing dynamics of growth across the rheumatoid arthritis stem cell therapy market due to the novel coronavirus outbreak. The researchers have analyzed every small aspect of the COVID-19 impact and then added them in the report.

To understand how our report can bring difference to your business strategy,Ask for a brochure

Rheumatoid Arthritis Stem Cell Therapy Market: Competitive Landscape

The rheumatoid arthritis stem cell therapy market can be categorized as highly fragmented due to the presence of numerous players competing for the top position. Research and development activities form an important part to discover novel insights across varied rheumatoid arthritis stem cell therapy mechanisms.

Some well-established participants in the rheumatoid arthritis stem cell therapy market are International Stem Cell Corporation, Mesoblast Ltd., Regeneus Ltd, International Stem Cell Corporation, ReNeuron Group plc, and TiGenix.

Request for Analysis of COVID19 Impact on Rheumatoid Arthritis Stem Cell Therapy Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78655

Rheumatoid Arthritis Stem Cell Therapy Market: Growth-Inducing Advantages

Many advantages are attached to the rheumatoid arthritis stem cell therapy market that helps in bringing extensive growth opportunities. Although rheumatoid arthritis stem cell therapy is not a full-proof treatment for curing arthritis, it can reduce inflammation and also aid in the stabilization of the immune system. In addition, the rheumatoid arthritis stem cell therapy has also shown long-term efficacy in overcoming inflammation caused due to arthritis. Government support is also proving to be a major growth factor for the rheumatoid arthritis stem cell therapy market.

Furthermore, research has also highlighted the improvement in sleep, diet, and physical strength among the patients after cell therapy.

Pre-Book Rheumatoid Arthritis Stem Cell Therapy Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=78655&ltype=S

Rheumatoid Arthritis Stem Cell Therapy Market: Key Findings

The research and development activities in the rheumatoid arthritis stem cell therapy market are always in full swing and are involved in exploring novel findings that help in increasing the graph of growth. For instance, scientists recently discovered a new cell, known as PRIME cell that appears in the bloodstream of rheumatoid arthritis patients just before the inflammation begins. Such findings may help the players in the rheumatoid arthritis stem cell therapy market to discover novel mechanisms of rheumatoid arthritis stem cell therapy.

Rheumatoid Arthritis Stem Cell Therapy Market: Geographical Analysis

The rheumatoid arthritis stem cell therapy market can be geographically segmented into North America, Latin America, the Middle East and Africa, Asia Pacific, and Europe. North America may emerge as a champion growth contributor for the rheumatoid arthritis stem cell therapy market during the forecast period of 2020-2030. The presence of numerous key players in the region can serve as a major growth factor.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,90 Sate Street, Suite 700,Albany, NY 12207Tel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.com/

Read More Reports: https://www.prnewswire.com/news-releases/expanding-awareness-about-early-detection-of-breast-cancer-to-invite-growth-for-breast-imaging-market-north-america-to-bag-title-of-significant-regional-contributor-opines-tmr-301096037.html

See the rest here:
Rheumatoid Arthritis Stem Cell Therapy Market Business Opportunities and Growth Challenges Report - The Daily Chronicle

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will participate in the following upcoming investor conferences.

Authorized for release by the Chief Executive Officer of AVITA Therapeutics, Inc.

ABOUT AVITA THERAPEUTICS, INC.

AVITA Therapeutics is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Therapeutics patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Therapeutics first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

Continued here:
AVITA Therapeutics to Participate in Upcoming Investor Conferences - Business Wire

MediSpin XL high-volume industrial electrospinning platform for both medical devices and new drug delivery applications

WAALRE, The Netherlands, September 03, 2020 / B3C newswire / -- IME Medical Electrospinning, a global leader in electrospun medical devices and regenerative medicine, today announced it has successfully raised 3 million in equity financing and debt from existing shareholder TIIN Capital, new investors Borski Fund and Lumana Invest, and from Rabobank Region Eindhoven.

In 2019 IME launched the MediSpin XL production platform for large-scale industrial manufacturing of reproducible and scalable electrospun nanofiber-based scaffolds for Class I, II and III medical devices, marking a global breakthrough in the controlled large-scale production of batch-consistent, high-quality end-products in volume. To be able to manage the electrospinning control parameters unlocks its full potential for industrial medical applications.

MediSpin XL creates nanometer solutions that mimic the natural extracellular matrix in the human body. Human cells recognize and infiltrate these scaffolds, encouraging quick and efficient tissue integration, resulting in natural tissue restoration while minimizing medical complications.

The vast array of innovative applications include fully bioresorbable stents, heart valves, nanofibrous meshes and many other new devices for a.o. local drug delivery, implantables and tissue engineering.

Judith Heikoop, Managing Director of IME Medical Electrospinning, says: The additional financing and support of new shareholders Borski Fund, Lumana Invest and existing shareholder TIIN Capital will enable us to further strengthen our MediSpin XL electropinning platform and industrial production capabilities for medical devices and drug delivery applications. Combining our state of the art production platform with our broadened focus, underpins our strong belief in the strategic goal of becoming the leader in large-scale production of both medical devices and drug delivery solutions. Now we can jointly develop other breakthrough medical solutions with our pharma partners and expand our operations. The support of both our existing and new investors fills me with pride and shows that they recognize the large value-adding component of our game-changing capabilities.

Ramon Solberg, Founder and together with Judith Heikoop, Managing Director of IME Medical Electrospinning, adds: This new successful financing round enables us to further capitalize on our scientific and technical findings over the past decade, growing our product portfolio from regenerative medtech solutions to the even broader and promising global market for targeted drug delivery solutions.

About Medical ElectrospinningApplying specific polymers, IMEs advanced equipment creates fiber-based medical device solutions that mimic the natural human extracellular matrix in nanometer and micrometer format for implants and membranes in the human body. Human cells recognize this artificial matrix (scaffold) as the bodys own facilitating the repair of the damaged tissue for heart valves, blood vessels, nerves, tendons, skin and bone etc. This is in contrast to implants and membranes of traditional structures, which are seen as foreign and therefore can lead to scar tissue or rejection phenomena. The MediSpin XL platform has been developed specifically for MedTech industrial manufacturing of medical devices and is now also suitable for pharmaceutical drug delivery applicaitons and ensures the firm control of the crucial parameters of the electrospinning process, leading to identical and consistent end-products.

About Borski FundDutch Borski Fund believes in diversity, gender equality and fair opportunities. It invests in female entrepreneurs because it wants to build good companies with them, because their talent needs to be better utilized, because Borski Fund is their natural partner, because is has the network that matters to them. Because it is important that innovation is stimulated by female entrepreneurs.

About Lumana InvestDutch Lumana is an investment company founded by entrepreneurs. Lumana Invest stands for committed stakeholdership supporting management in strategic issues. With an investment horizon for an indefinite period, Lumana has a unique investment approach. In addition, the fund managers responsible for entering into and supervising participations are also founders and co-shareholders of Lumana. Lumana prefers to invest in start-ups in new markets and new techniques. Exploring boundaries with management and, if possible, pushing them further. Forward-looking and with the ambition to permanently change the future. "Lumanai" has been freely translated from Samoan meaning future.

About TIIN Capital TIIN Capital is a Naarden, the Netherlands, based fund manager and uses a network of approximately 1.000 angel investors. Entrepreneurship, knowledge of the market, technology (from the network) and capital are of great added value for the investments. As entrepreneurial investors, TIIN Capital accelerates growth-oriented companies with active growth and buy & build strategies, where innovative entrepreneurship is central to be able to take the next step.

About IME Medical ElectrospinningFor over ten years, IME Medical Electrospinning has been a leading player in the field of developing and implementing electrospinning processes and equipment for the manufacturing of medical devices for (regenerative) medicine and drug delivery. Electrospinning is a flexible process for producing extremely thin fibers and structures that have excellent properties to help regenerate human tissue. IME Medical Electrospinning has developed an unique set of innovations in electrospinning technology for the reproducible and scalable production of electrospun material under tightly controlled conditions required for the MedTech and Pharma market. Customers and scientific partners include the MedTech and Pharma industry, scientists and health institutions.

Contacts

IME Medical Electrospinning, Waalre, The NetherlandsJudith Heikoop M.Sc. Ph.D.+31 40 28 27 956This email address is being protected from spambots. You need JavaScript enabled to view it.

For mediaLifeSpring Life Sciences Communication, AmsterdamLon Melens+31 6 538 16 427This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Humans; Nanofibers; Equipment and Supplies; Drug Delivery Systems; Biomimetics; Extracellular Matrix; Capital Financing; Industry; Tissue Engineering; Heart Valves; Drug Delivery Systems; Stents

Published by B3C newswire

Read the original post:
IME Medical Electrospinning Secured 3 Million in New Financing From Dutch VCs Borski Fund, Lumana Invest, TIIN Capital and From Rabobank to Further...

BASKING RIDGE, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the Advanced Therapies Congress & Expo being held virtually September 8-11, 2020.

Title: Repair of the microcirculation reverses ischemic tissue damagePresenter: Douglas W. Losordo, M.D., EVP, Global Head of R&D and Chief Medical OfficerTrack: Stem Cells and Regenerative MedicineDate/Time: Wednesday, September 9, 2020 at 12:00 p.m. (BST)

Title: Roundtable discussion: Development of regenerative medicines for cardiovascular indicationsPresenter: David J. Mazzo, Ph.D., President and Chief Executive OfficerTrack: Stem Cells and Regenerative MedicineDate/Time: Wednesday, September 9, 2020 at 4:00 p.m. (BST)

Additional information can be found on the conference website.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Companys current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming weeks as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (CLI) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (CMD); and CLBS14, a Regenerative Medicine Advanced Therapy (RMAT) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the FDA) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (NORDA). For more information on the company, please visit http://www.caladrius.com.

Contact:

Investors:Caladrius Biosciences, Inc.John MendittoVice President, Investor Relations and Corporate CommunicationsPhone:+1-908-842-0084Email:jmenditto@caladrius.comMedia:W2O GroupChristiana PascalePhone: +1-212-257-6722Email:cpascale@w2ogroup.com

Follow this link:
Caladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020 - Yahoo Finance

DUBLIN, Sept. 2, 2020 /PRNewswire/ -- The "Global Cord Blood Banking Industry Report 2020" report has been added to ResearchAndMarkets.com's offering.

This report presents the number of cord blood units stored in inventory by the largest cord blood banks worldwide and the number of cord blood units (CBUs) released by registries across the world for hematopoietic stem cell (HSC) transplantation. Although cord blood is now used to treat more than 80 different diseases, this number could substantially expand if applications related to regenerative medicine start receiving approvals in major healthcare markets worldwide.

From the early 1900s through the mid-2000s, the global cord blood banking industry expanded rapidly, with companies opening for business in all major markets worldwide. From 2005 to 2010, the market reached saturation and stabilized.

Then, from 2010 to 2020, the market began to aggressively consolidate. This has created both serious threats and unique opportunities within the industry.

Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation. There are also emerging opportunities for the industry, such as accelerated regulatory pathways for cell therapies in leading healthcare markets worldwide and expanding applications for cell-based therapies. In particular, MSCs from cord tissue (and other sources) are showing intriguing promise in the treatment and management of COVID-19.

Cord Blood Industry Trends

Within recent years, new themes have been impacting the industry, including the pairing of stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including umbilical cord tissue storage, placental blood and tissue, amniotic fluid and tissue, and dental pulp. Cord blood banks are also investigating means of becoming integrated therapeutic companies. With hundreds of companies offering cord blood banking services worldwide, maturation of the market means that each company is fighting harder for market share.

Growing numbers of investors are also entering the marketplace, with M&A activity accelerating in the U.S. and abroad. Holding companies are emerging as a global theme, allowing for increased operational efficiency and economy of scale. Cryoholdco has established itself as the market leader within Latin America. Created in 2015, Cryoholdco is a holding company that will control nearly 270,000 stem cell units by the end of 2020. It now owns a half dozen cord blood banks, as well as a dental stem cell storage company.

Globally, networks of cord blood banks have become commonplace, with Sanpower Group establishing its dominance in Asia. Although Sanpower has been quiet about its operations, it holds 4 licenses out of only 7 issued provincial-level cord blood bank licenses in China. It has reserved over 900,000 cord blood samples in China, and its reserves amount to over 1.2 million units when Cordlife' reserves within Southeast Asian countries are included. This positions Sanpower Group and it's subsidiary Nanjing Cenbest as the world's largest cord blood banking operator not only in China and Southeast Asia but in the world.

The number of cord blood banks in Europe has dropped by more than one-third over the past ten years, from approximately 150 to under 100. The industry leaders in this market segment include FamiCord Group, who has executed a dozen M&A transactions, and Vita34, who has executed approximately a half dozen. Stemlab, the largest cord blood bank in Portugal, also executed three acquisition deals prior to being acquired by FamiCord. FamiCord is now the leading stem cell bank in Europe and one of the largest worldwide.

Cord Blood Expansion Technologies

Because cord blood utilization is largely limited to use in pediatric patients, growing investment is flowing into ex vivo cord blood expansion technologies. If successful, this technology could greatly expand the market potential for cord blood, encouraging its use within new markets, such as regenerative medicine, aging, and augmented immunity.

Key strategies being explored for this purpose include:

Currently, Gamida Cell, Nohla Therapeutics, Excellthera, and Magenta Therapeutics have ex vivo cord blood expansion products proceeding through clinical trials. Growing numbers of investors have also entered the cord blood banking marketplace, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC, and Excalibur.

Cord Blood Banking by Region

Within the United States, most of the market share is controlled by three major players: Cord Blood Registry (CBR), Cryo-Cell, and ViaCord. CBR has been traded twice, once in 2015 to AMAG Pharmaceuticals for $700 million and again in 2018 to GI Partners for $530 million. CBR also bought Natera's Evercord Cord Blood Banking business in September 2019. In total, CBR controls over 900,000 cord blood and tissue samples, making it one of the largest cord blood banks worldwide.

In China, the government controls the industry by authorizing only one cord blood bank to operate within each province, and official government support, authorization, and permits are required. Importantly, the Chinese government announced in late 2019 that it will be issuing new licenses for the first time, expanding from the current 7 licensed regions for cord blood banking to up to 19 regions, including Beijing.

In Italy and France, it is illegal to privately store one's cord blood, which has fully eliminated the potential for a private market to exist within the region. In Ecuador, the government created the first public cord blood bank and instituted laws such that private cord blood banks cannot approach women about private cord blood banking options during the first six months of pregnancy. This created a crisis for private banks, forcing most out of business.

Recently, India's Central Drugs Standard Control Organization (CDSCO) restricted commercial banking of stem cells from most biological materials, including cord tissue, placenta, and dental pulp stem cells - leaving only umbilical cord blood banking as permitted and licensed within the country.

While market factors vary by geography, it is crucial to have a global understanding of the industry, because research advances, clinical trial findings, and technology advances do not know international boundaries. The cord blood market is global in nature and understanding dynamics within your region is not sufficient for making strategic, informed, and profitable decisions.

Overall, the report provides the reader with the following details and answers the following questions:

1. Number of cord blood units cryopreserved in public and private cord blood banks globally2. Number of hematopoietic stem cell transplants (HSCTs) globally using cord blood cells3. Utilization of cord blood cells in clinical trials for developing regenerative medicines4. The decline of the utilization of cord blood cells in HSC transplantations since 20055. Emerging technologies to influence the financial sustainability of public cord blood banks6. The future scope for companion products from cord blood7. The changing landscape of cord blood cell banking market8. Extension of services by cord blood banks9. Types of cord blood banks10. The economic model of public cord blood banks11. Cost analysis for public cord blood banks12. The economic model of private cord blood banks13. Cost analysis for private cord blood banks14. Profit margins for private cord blood banks15. Pricing for processing and storage in private banks16. Rate per cord blood unit in the U.S. and Europe17. Indications for the use of cord blood-derived HSCs for transplantations18. Diseases targeted by cord blood-derived MSCs in regenerative medicine19. Cord blood processing technologies20. Number of clinical trials, number of published scientific papers and NIH funding for cord blood research21. Transplantation data from different cord blood registries

Key questions answered in this report are:

1. What are the strategies being considered for improving the financial stability of public cord blood banks?2. What are the companion products proposed to be developed from cord blood?3. How much is being spent on processing and storing a unit of cord blood?4. How much does a unit of cryopreserved cord blood unit fetch on release?5. Why do most public cord blood banks incur a loss?6. What is the net profit margin for a private cord blood bank?7. What are the prices for processing and storage of cord blood in private cord blood banks?8. What are the rates per cord blood units in the U.S. and Europe?9. What are the revenues from cord blood sales for major cord blood banks?10. Which are the different accreditation systems for cord blood banks?11. What are the comparative merits of the various cord blood processing technologies?12. What is to be done to increase the rate of utilization of cord blood cells in transplantations?13. Which TNC counts are preferred for transplantation?14. What is the number of registered clinical trials using cord blood and cord tissue?15. How many clinical trials are involved in studying the expansion of cord blood cells in the laboratory?16. How many matching and mismatching transplantations using cord blood units are performed on an annual basis?17. What is the share of cord blood cells used for transplantation from 2000 to 2020?18. What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?19. Which are the top ten countries for donating cord blood?20. What are the diseases targeted by cord blood-derived MSCs within clinical trials?

Key Topics Covered

1. REPORT OVERVIEW1.1 Statement of the Report1.2 Executive Summary1.3 Introduction1.3.1 Cord Blood: An Alternative Source for HPSCs1.3.2 Utilization of Cord Blood Cells in Clinical Trials1.3.3 The Struggle of Cord Blood Banks1.3.4 Emerging Technologies to Influence Financial Sustainability of Banks1.3.4.1 Other Opportunities to Improve Financial Stability1.3.4.2 Scope for Companion Products1.3.5 Changing Landscape of Cord Blood Cell Banking Market1.3.6 Extension of Services by Cord Blood Banks

2. CORD BLOOD & CORD BLOOD BANKING: AN OVERVIEW2.1 Cord Blood Banking (Stem Cell Banking)2.1.1 Public Cord Blood Banks2.1.1.1 Economic Model of Public Cord Blood Banks2.1.1.2 Cost Analysis for Public Banks2.1.1.3 Relationship between Costs and Release Rates2.1.2 Private Cord Blood Banks2.1.2.1 Cost Analysis for Private Cord Blood Banks2.1.2.2 Economic Model of Private Banks2.1.3 Hybrid Cord Blood Banks2.2 Globally Known Cord Blood Banks2.2.1 Comparing Cord Blood Banks2.2.2 Cord Blood Banks in the U.S.2.2.3 Proportion of Public, Private and Hybrid Banks2.3 Percent Share of Parents of Newborns Storing Cord Blood by Country/Region2.4 Pricing for Processing and Storage in Commercial Banks2.4.1 Rate per Cord Blood Unit in the U.S. and Europe2.5 Cord Blood Revenues for Major Cord Blood Banks

3. CORD BLOOD BANK ACCREDITATIONS3.1 American Association of Blood Banks (AABB)3.2 Foundation for the Accreditation of Cellular Therapy (FACT)3.3 FDA Registration3.4 FDA Biologics License Application (BLA) License3.5 Investigational New Drug (IND) for Cord Blood3.6 Human Tissue Authority (HTA)3.7 Therapeutic Goods Act (TGA) in Australia3.8 International NetCord Foundation3.9 AABB Accredited Cord Blood Facilities3.10 FACT Accreditation for Cord Blood Banks

4. APPLICATIONS OF CORD BLOOD CELLS4.1 Hematopoietic Stem Cell Transplantations with Cord Blood Cells4.2 Cord Cells in Regenerative Medicine

5. CORD BLOOD PROCESSING TECHNOLOGIES5.1 The Process of Separation5.1.1 PrepaCyte-CB5.1.2 Advantages of PrepaCyte-CB5.1.3 Treatment Outcomes with PrepaCyte-CB5.1.4 Hetastarch (HES)5.1.5 AutoXpress (AXP)5.1.6 SEPAX5.1.7 Plasma Depletion Method (MaxCell Process)5.1.8 Density Gradient Method5.2 Comparative Merits of Different Processing Methods5.2.1 Early Stage HSC Recovery by Technologies5.2.2 Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood5.2.3 Late Stage Recovery of HSCs from Cord Blood5.3 HSC (CD45+) Recovery5.4 Days to Neutrophil Engraftment by Technology5.5 Anticoagulants used in Cord Blood Processing5.5.1 Type of Anticoagulant and Cell Recovery Volume5.5.2 Percent Cell Recovery by Sample Size5.5.3 TNC Viability by Time Taken for Transport and Type of Anticoagulant5.6 Cryopreservation of Cord Blood Cells5.7 Bioprocessing of Umbilical Cord Tissue (UCT)5.8 A Proposal to Improve the Utilization Rate of Banked Cord Blood

6. CORD BLOOD CLINICAL TRIALS, SCIENTIFIC PUBLICATIONS & NIH FUNDING6.1 Cord Blood Cells for Research6.2 Cord Blood Cells for Clinical Trials6.2.1 Number of Clinical Trials involving Cord Blood Cells6.2.2 Number of Clinical Trials using Cord Blood Cells by Geography6.2.3 Number of Clinical Trials by Study Type6.2.4 Number of Clinical Trials by Study Phase6.2.5 Number of Clinical Trials by Funder Type6.2.6 Clinical Trials Addressing Indications in Children6.2.7 Select Three Clinical Trials Involving Children6.2.7.1 Sensorineural Hearing Loss (NCT02038972)6.2.7.2 Autism Spectrum (NCT02847182)6.2.7.3 Cerebral Palsy (NCT01147653)6.2.8 Clinical Trials for Neurological Diseases using Cord Blood and Cord Tissue6.2.9 UCB for Diabetes6.2.10 UCB in Cardiovascular Clinical Trials6.2.11 Cord Blood Cells for Auto-Immune Diseases in Clinical Trials6.2.12 Cord Tissue Cells for Orthopedic Disorders in Clinical Trials6.2.13 Cord Blood Cells for Other Indications in Clinical Trials6.3 Major Diseases Addressed by Cord Blood Cells in Clinical Trials6.4 Clinical Trials using Cord Tissue-Derived MSCs6.5 Ongoing Clinical Trials using Cord Tissue6.5.1 Cord Tissue-Based Clinical Trials by Geography6.5.2 Cord Tissue-Based Clinical Trials by Phase6.5.3 Cord Tissue-Based Clinical Trials by Sponsor Types6.5.4 Companies Sponsoring in Trials using Cord Tissue-Derived MSCs6.6 Wharton's Jelly-Derived MSCs in Clinical Trials6.6.1 Wharton's Jelly-Based Clinical Trials by Phase6.6.2 Companies Sponsoring Wharton's Jelly-Based Clinical Trials6.7 Clinical Trials Involving Cord Blood Expansion Studies6.7.1 Safe and Feasible Expansion Protocols6.7.2 List of Clinical Trials involved in the Expansion of Cord Blood HSCs6.7.3 Expansion Technologies6.8 Scientific Publications on Cord Blood6.9 Scientific Publications on Cord Tissue6.10 Scientific Publications on Wharton's Jelly-Derived MSCs6.11 Published Scientific Papers on Cord Blood Cell Expansion6.12 NIH Funding for Cord Blood Research

7. PARENT'S AWARENESS AND ATTITUDE TOWARDS CORD BLOOD BANKING7.1 Undecided Expectant Parents7.2 The Familiar Cord Blood Banks Known by the Expectant Parents7.3 Factors Influencing the Choice of a Cord Blood Bank

8. CORD BLOOD: AS A TRANSPLANTATION MEDICINE8.1 Comparisons of Cord Blood to other Allograft Sources8.1.1 Major Indications for HCTs in the U.S.8.1.2 Trend in Allogeneic HCT in the U.S. by Recipient Age8.1.3 Trends in Autologous HCT in the U.S. by Recipient Age8.2 HCTs by Cell Source in Adult Patients8.2.1 Transplants by Cell Source in Pediatric Patients8.3 Allogeneic HCTs by Cell Source8.3.1 Unrelated Donor Allogeneic HCTs in Patients &lessThan;18 Years8.4 Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity8.4.1 Likelihood of Finding an Unrelated Cord Blood Unit for Patients &lessThan;20 Years8.5 Odds of using a Baby's Cord Blood8.6 Cord Blood Utilization Trends8.7 Number of Cord Blood Donors Worldwide8.7.1 Number of CBUs Stored Worldwide8.7.2 Cord Blood Donors by Geography8.7.2.1 Cord Blood Units Stored in Different Geographies8.7.2.2 Number of Donors by HLA Typing8.7.3 Searches Made by Transplant Patients for Donors/CBUs8.7.4 Types of CBU Shipments (Single/Double/Multi)8.7.5 TNC Count of CBUs Shipped for Children and Adult Patients8.7.6 Shipment of Multiple CBUs8.7.7 Percent Supply of CBUs for National and International Patients8.7.8 Decreasing Number of CBU Utilization8.8 Top Ten Countries in Cord Blood Donation8.8.1 HLA Typed CBUs by Continent8.8.2 Percentage TNC of Banked CBUs8.8.3 Total Number of CBUs, HLA-Typed Units by Country8.9 Cord Blood Export/Import by the E.U. Member States8.9.1 Number of Donors and CBUs in Europe8.9.2 Number of Exports/Imports of CBUs in E.U.8.10 Global Exchange of Cord Blood Units

9. CORD BLOOD CELLS AS THERAPEUTIC CELL PRODUCTS IN CELL THERAPY9.1 MSCs from Cord Blood and Cord Tissue9.1.1 Potential Neurological Applications of Cord Blood-Derived Cells9.1.2 Cord Tissue-Derived MSCs for Therapeutic use9.1.2.1 Indications Targeted by UCT-MSCs in Clinical Trials9.2 Current Consumption of Cord Blood Units by Clinical Trials9.3 Select Cord Blood Stem Cell Treatments in Clinical Trials9.3.1 Acquired Hearing Loss (NCT02038972)9.3.2 Autism (NCT02847182)9.3.3 Cerebral Palsy (NCT03087110)9.3.4 Hypoplastic Left Heart Syndrome (NCT01856049)9.3.5 Type 1 Diabetes (NCT00989547)9.3.6 Psoriasis (NCT03765957)9.3.7 Parkinson's Disease (NCT03550183)9.3.8 Signs of Aging (NCT04174898)9.3.9 Stroke (NCT02433509)9.3.10 Traumatic Brain Injury (NCT01451528)

10. MARKET ANALYSIS10.1 Public vs. Private Cord Blood Banking Market10.2 Cord Blood Banking Market by Indication

11. PROFILES OF SELECT CORD BLOOD BANKS11.1 AllCells11.1.1 Whole Blood11.1.2 Leukopak11.1.3 Mobilized Leukopak11.1.4 Bone Marrow11.1.5 Cord Blood11.2 AlphaCord LLC11.2.1 NextGen Collection System11.3 Americord Registry, Inc.11.3.1 Cord Blood 2.011.3.2 Cord Tissue11.3.3 Placental Tissue 2.011.4 Be The Match11.4.1 Hub of Transplant Network11.4.2 Partners of Be The Match11.4.3 Allogeneic Cell Sources in Be The Match Registry11.4.4 Likelihood of a Matched Donor on Be The Match by Ethnic Background11.5 Biocell Center Corporation11.5.1 Chorionic villi after Delivery11.5.2 Amniotic Fluid and Chorionic Villi during Pregnancy11.6 BioEden Group, Inc.11.6.1 Differences between Tooth Cells and Umbilical Cord Cells11.7 Biovault Family11.7.1 Personalized Cord Blood Processing11.8 Cell Care11.9 Cells4Life Group, LLP11.9.1 Cells4Life's pricing11.9.2 TotiCyte Technology11.9.3 Cord Blood Releases11.10 Cell-Save11.11 Center for International Blood and Marrow Transplant Research (CIBMTR)11.11.1 Global Collaboration11.11.2 Scientific Working Committees11.11.3 Medicare Clinical Trials and Studies11.11.4 Cellular Therapy11.12 Crio-Cell International, Inc.11.12.1 Advanced Collection Kit11.12.2 Prepacyte-CB11.12.3 Crio-Cell International's Pricing11.12.4 Revenue for Crio-Cell International11.13 Cord Blood Center Group11.13.1 Cord Blood Units Released11.14 Cordlife Group, Ltd.11.14.1 Cordlife's Cord Blood Release Track Record11.15 Core23 Biobank11.16 Cord Blood Registry (CBR)11.17 CordVida11.18 Crioestaminal11.18.1 Cord Blood Transplantation in Portugal11.19 Cryo-Cell International, Inc.11.19.1 Processing Method11.19.2 Financial Results of the Company11.20 CryoHoldco11.21 Cryoviva Biotech Pvt. Ltd11.22 European Society for Blood and Bone Marrow Transplantation (EBMT)11.22.1 EBMT Transplant Activity11.23 FamiCord Group11.24 GeneCell International11.25 Global Cord Blood Corporation11.25.1 The Company's Business11.26 HealthBaby Hong Kong11.26.1 BioArchive System Service Plan11.26.2 MVE Liquid Nitrogen System11.27 HEMAFUND11.28 Insception Lifebank11.29 LifebankUSA11.29.1 Placental Banking11.30 LifeCell International Pvt. Ltd.11.31 MiracleCord, Inc.11.32 Maze Cord Blood Laboratories11.33 New England Cord Blood Bank, Inc.11.34 New York Cord Blood Center (NYBC)11.34.1 Products11.34.2 Laboratory Services11.35 PacifiCord11.35.1 FDA-Approved Sterile Collection Bags11.35.2 AXP Processing System11.35.3 BioArchive System11.36 ReeLabs Pvt. Ltd.11.37 Smart Cells International, Ltd.11.38 Stem Cell Cryobank11.39 StemCyte, Inc.11.39.1 StemCyte Sponsored Clinical Trials11.39.1.1 Spinal Cord Injury Phase II11.39.1.2 Other Trials11.40 Transcell Biolife11.40.1 ScellCare11.40.2 ToothScell11.41 ViaCord11.42 Vita 34 AG11.43 World Marrow Donor Association (WMDA)11.43.1 Search & Match Service11.44 Worldwide Network for Blood & Marrow Transplantation (WBMT)

For more information about this report visit https://www.researchandmarkets.com/r/7bm9lx

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Originally posted here:
Global Cord Blood Banking Market 2020 with Analysis of 44 Industry Players - PRNewswire

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Regenerative Medicine market.

Trusted Business Insights presents an updated and Latest Study on Regenerative Medicine Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Regenerative Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

The global regenerative medicine market size was USD 23,841.5 Million in 2018 and is Projected to Reach USD 151,949.5 Million by 2026, Exhibiting a CAGR of 26.1% between 2019 and 2026.

We have updated Regenerative Medicine Market with respect to COVID-19 Impact.Inquire before buying

Regenerative medicine (RM) involves using cells, tissues, or genetic material to treat and manage diseases. Regenerative medicine is an emerging field that aims to repair, replace or regenerate damaged tissue or organ. The U.S. National Institutes of Health includes cell therapy, gene therapy, biomaterials and tissue engineering into regenerative medicine. Regenerative medicine holds potential to treat incurable chronic diseases and conditions such as Alzheimer disease, Parkinsons disease, diabetes and others. According to the Alliance for Regenerative Medicine, approximately around 1,028 clinical trials are ongoing on regenerative medicine worldwide. Around USD 13.3 Bn global financing were raised in 2018 by investment into regenerative medicine. The increased investment by key market players in the research and development of the regenerative medicine is one of the major factor anticipated to drive the regenerative medicine market growth during the forecast period.

Market Segmentation

Increased investment in the research and development of regenerative by the key market players is one of the major factor driving the global market

Increasing investment by private and government organization in the development of the regenerative medicine is one of the factors expected to propel regenerative medicine industry dynamics. For instance, in March 2018, SanBio Group signed an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC for the development and contract manufacturing of regenerative medicines. Rising prevalence of chronic and genetic disorders and increased healthcare expenditure by developed and developing countries are some of the key factors impelling the regenerative medicine market growth.

Additionally, presence of the strong product pipeline in stem cell and gene therapy by various research institutes and key market players is one if the major factor anticipated to boost the growth of the market during the forecast period of 2018-2026. However, the growing demand for organ transplantation in developed and developing countries and the commercialization of regenerative medicine are some of the key elements anticipated to supplement the growth of the regenerative medicine market trends throughout the forecast period. Increased use of skin substitutes, grafts, bone matrix and other tissue engineered regenerative medicine is one of the prominent factor for the growth of the market.

Based on the type, the regenerative medicine industry segments includes cell therapy, gene therapy, tissue engineering, and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology, and others.

On the basis of distribution channel, the global regnerative medicine segments includes hospitals, clinics, and others. Cell therapy segmented is expected to register comparatively high CAGR during the forecast period due to increased research and product development in the field of stem cells.Regional Analysis

Asia Pacific is anticipated to register comparatively higher CAGR during the forecast period due to increased adoption of the platelet rich plasma therapy and growing awareness among the population about stem cell therapy and regenerative medicine

North America generated maximum revenue of USD 9,128.2 Mn in 2018 and is expected to dominate the market throughout the forecast period. Due to presence of substantial number of key market players based in U.S., presence of research institutes involved in development of novel therapeutics and availability of advanced technologies are attributive to the high number of clinical trials in North America. Asia Pacific is anticipated to witness exponential growth during the forecast period owing to expansion of infrastructure and facilities to accelerate stem cell research in developing countries. In April 2013, the Japan Ministry of Health, Labor and Welfare approved Regenerative Medicine law.

Asia Pacific Regenerative Medicine Market Size, 2018

The imposition of the law increased the number of the clinical development of regenerative and cell-based therapies. This led to drive the growth of the regenerative medicine market in the region. Additionally, Chinese government has approved several research related to human embryonic stem cells in order to encourage researchers to explore the clinical potential of these cells in China. Furthermore, rising aging population, increasing medical needs, and changing lifestyle are some of the other factors influencing the growth of the global regenerative market in the Asia Pacific region. Latin America, and Middle East & Africa region hold large potential for the market during 2019-2026.

Key Market Drivers

CELGENE CORPORATION, Medtronic, and American CryoStem Corporation Account for the Highest Market Share in Terms of Revenue

CELGENE CORPORATION, is a leading player in the global regenerative medicines, owing to its strong portfolio in wound care and orthopedics and more investment in the research and development of the regenerative medicine. In order to strengthen the market position, key market players are focusing on the introduction of organ development and treatment of chronic diseases in the global market. CELGENE CORPORATION, Medtronic, and American CryoStem Corporation, dominated the regenerative medicine market in 2018. Other players operating in the market are Avita Medical, Osiris Therapeutics, Inc., Tissue Regenix, Wright Medical Group N.V., Smith & Nephew, Integra LifeSciences Corporation and others.

List of Companies Profiled

Report Coverage

The potential to directly alter human genes was first recognized nearly more than 50 years ago. Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals. Regenerative medicine also comprises of therapeutic tissue engineering and biomaterials engineered substances used in medical applications to supplement or replace a natural body function. The increased number of the clinical trials and the use of the regenerative medicine for the development of the medicine to treat chronic diseases are some of the factors propelling the regenerative medicine market trends.

The report provides qualitative and quantitative insights on the regenerative medicine industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segments include type, application, distribution channel, and geography. On the basis of the type, the market is segmented into cell therapy, gene therapy, tissue engineering and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology and others. On the basis of distribution channel, the regenerative medicine market is segmented into hospitals, clinics and others. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the regenerative medicine market report comprises analysis of the industrydynamics and competitive landscape. Various key insights provided in the report are prevalence and incidence of diabetes by key countries, advancements in insulin delivery devices, recent industry developments such as mergers & acquisitions, pricing analysis, technological advancements, and key industry trends.

SEGMENTATION

By Product

By Application

By Distribution Channel

By Geography

Key Industry Developments

In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease.

In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah.In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair defects reconstruction in a one-step procedure.

Looking for more? Check out our repository for all available reports on Regenerative Medicine in related sectors.

Quick Read Table of Contents of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read the original:
Global regenerative medicine market size was USD 23841.5 Million in 2018 and is Projected to Reach USD 151949.5 Million by 2026, Exhibiting a CAGR of...

Gene therapy generally relies on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In case of CRISPR-based gene therapies, molecular scissors can then snip out a defective gene, add in a missing sequence or enact a temporary change in its expression, but the bodys immune response to AAV can thwart the whole endeavor.

To overcome that obstacle, researchers at the University of Pittsburgh created a system that uses CRISPR in a different way. Their system briefly suppresses genes that are related to AAV antibody production so the virus can deliver its cargo unimpeded. These results published today in Nature Cell Biology.

Many clinical trials fail because of the immune response against AAV gene therapy, said study co-senior author Samira Kiani, associate professor of pathology in Pitt's School of Medicine and member of the Pittsburgh Liver Research Center (PLRC) and McGowan Institute for Regenerative Medicine. And then you cant readminister the shot because people have developed immunity.

So Kiani and her long-time collaborator Mo Ebrahimkhani, associate professor of pathology at Pitt, member of PLRC and the McGowan Institute, set out to modify gene expression related to the bodys immune response to AAV. But this gene is important for normal immune function, so the researchers didnt want to shut it down forever, just tamp it down momentarily.

Since CRISPR is such a convenient system for editing the genome, the pair figured they would put it to use for altering the master switches that orchestrate genes involved in immune response.

Were hitting two birds with one stone, said Ebrahimkhani. You can use CRISPR to do your gene therapy, and you can also use CRISPR to control the immune response.

When the researchers treated mice with their CRISPR-controlled immune suppression system and then exposed them to AAV again, the animals didnt make more antibodies against the virus. These animals were more receptive to subsequent AAV-delivered gene therapy compared to controls.

Beyond gene therapy, the study also shows that CRISPR-based immune suppression can prevent or treat sepsis in mice, highlighting the potential for this tool to be broadly useful for a range of inflammatory conditions, including cytokine storm and acute respiratory distress syndrome, both of which can crop up with COVID-19, though more studies are needed to engineer safety features.

The main goal of this study was to develop CRISPR-based tools for inflammatory conditions, said study lead author Farzaneh Moghadam, a PhDstudent in Kianis lab. But when we looked at bone marrow samples, we saw that the group treated with our tool showed a lower immune response to AAV compared to the control group. That was very interesting, so we started exploring how this tool contributes to antibody formation against AAV and could potentially address safety and efficacy concerns with gene therapy trials.

Kiani co-founded SafeGen Therapeutics with the goal of bringing this technology to the clinic.

This study was supported by National Institute of Biomedical Imaging and Bioengineering, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, and a DARPA Young Faculty Award.

Additional authors on the study include graduate student Ryan LeGraw and researcher Jeremy Velazquez from Pitt.

See original here:
Editing Immune Response Could Make Gene Therapy More Effective - UPJ Athletics

In an August 28 special issue of the peer-reviewed online journal OBM Transplantation, stem cell biotechnology company Asymmetrex has now published a report describing how its technology for determining the specific dosage of therapeutic tissue stem cells works. The new technology is poised to revolutionize stem cell science and stem cell medicine by giving the long-needed means to quantity their essential focus, tissue stem cells.

BOSTON, Sept. 1, 2020 /PRNewswire-PRWeb/ --Stem cell biotechnology company, Asymmetrex, has been counting tissue stem cells like those used for bone marrow and cord blood transplantation therapies for a few years now. Recently, the company announced the issue of patents for its first-in-kind technology both in the U.S. and the U.K. However, until last Friday, August 28, Asymmetrex had not reported in the peer-reviewed academic literature how it achieves this feat that had been pursued by many distinguished labs for more than six decades.

Now in a report published in a special issue of OBM Transplantation, a peer-review journal for transplantation medicine research, Asymmetrex completes its introduction of the new technology to the fields of stem cell science and stem cell medicine. The report is the second invited article published in a special issue focused on the "Isolation and Characterization of Adult Therapeutic Cells."

The new report describes Asymmetrex's discovery of mathematical formulas, call algorithms, that can be used to determine the number of stem cells in complex tissue cell preparations, like experimental samples or patient treatments. The stem cell counting algorithms are specific for different types of tissue stem cells. So, the algorithms defined for blood stem cells are distinct from the algorithms for liver stem cells, or lung stem cells. Once an algorithm is defined by the Asymmetrex technology, it can be used repeatedly as a simple, rapid, and inexpensive test to determine the quantity and dosage of its specific tissue stem cell type.

Asymmetrex's founder and director, James L. Sherley, M.D., Ph.D., anticipated the August publication of the new algorithms in a talk given earlier at the 6th Annual Perinatal Stem Cell Society Congress in March of this year. Then and now, he says that he believes, "Now that the tissue stem cell counting algorithms are available, everything will change" in stem cell science and medicine.

Prior to Asymmetrex's technology, there was no method for counting tissue stem cells in research, medicine, or for any other of their many uses. So, the impact of the stem cell counting algorithms in research and medicine is far-reaching. Such information is a game changer for accelerating progress in stem cell science and stem cell medicine, including improving treatments like gene therapy whose success depends on targeting tissue stem cells. There will also be tremendous gains in cell biomanufacturing, drug development, and environmental toxicology, all whose capabilities are currently limited by the lack of a facile means to quantify tissue stem cells.

To make the new counting technology readily accessible for evaluation by the greater academic, medical, and industrial stem cell communities, Asymmetrex provides free tissue stem cell counting on its company website.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company's U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the "AlphaSTEM Test") for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

SOURCE Asymmetrex, LLC

Original post:
New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem...

Innovative Report on BiopreservationMarket with Competitive Analysis, New Business Developments, and Top Companies

A perfect mix of quantitative & qualitativeBiopreservationMarketMarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Biopreservation Market. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

Prominent players profiled in the study:, Thermo Fisher Scientific, GE Healthcare, Sigma-Aldrich(Merck), VWR International, Lonza, Biolife Solutions, STEMCELL Technologies, WAK-Chemie Medical GmbH

Sample Report with Latest Industry Trends @https://grandviewreport.com/sample/20475

This Report Provides an overview of the Biopreservationmarket, containing global revenue,global production, sales, and CAGR.Also describe Biopreservationproduct scope, market overview, market opportunities, market driving force, and market risks. The forecast and analysis of the Biopreservationmarket by type, application, and region are also presented. The next part of the report provides a full-scale analysis of Biopreservationcompetitive situation, sales, revenue and global market share of major players in the Biopreservationindustry. The basic information, as well as the profiles, applications, and specifications of products market performance along with Business Overview, are offered.

The key product type of Biopreservationmarket are:, Home-Brew Media, Pre-Formulated Media

BiopreservationMarket Outlook by Applications:, Drug Discovery, Regenerative Medicine, Biobanking

Geographical Regions:North America, Europe, Central & South America, Asia-Pacific, and the Middle East & Africa, etc.

Get Reasonable Discount on this Premium Report @https://grandviewreport.com/discount/20475

Scope of the BiopreservationReport:

This report covers the current scenario and growth prospects of the BiopreservationMarket for the period 2020-2025. The study is a professional and in-depth study with around tables and figures which provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the domain.

Finally, all aspects of the Global BiopreservationMarket are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and future prospects.

Browse Full[emailprotected]https://grandviewreport.com/industry-growth/Biopreservation-Market-20475

Read the original:
Biopreservation Market share forecast to witness considerable growth from 2020 to 2025 | By Top Leading Vendors , STEMCELL Technologies, WAK-Chemie...

As we get older, many of our bodys processes start slowing down. For instance, a cut on the hand will take longer to heal after middle age than in youth. That said, it still heals.

Unfortunately, this isnt the case for the cells at the back of the eye, which simply dont repair much after we pass age 65. This can lead to age-related macular degeneration (AMD), the primary cause of vision loss in older adults. Over 2 million cases were reported in the U.S. in 2010, and the National Eye Institute estimates AMD will affect more than 3.5 million adults in the country by 2030.

Researchers at UC Santa Barbara have overcome a major hurdle in creating a platform to test therapies for this disease, the most common form of which currently has no treatment. The results appear in the journal PLOS ONE.

Our sharpest vision occurs at the center of the retina, in an area called the macula. This region is packed full of cones, the cells that are necessary for seeing in detail, said author Pete Coffey, a researcher at UCSBs Neuroscience Research Institute. They are the cells that are involved in reading, recognizing faces, the ability to drive, et cetera.

Just behind them is a layer of retinal pigment epithelial (RPE) cells. These are responsible for maintaining the health of our rods and cones, the eyes photo receptors. And these are the cells that stop working properly in AMD.

Age-related macular degeneration comes in two forms. Wet AMD occurs when blood vessels infiltrate the retina. There are treatments for this variety, which aim to prevent the growth of blood vessels where theyre not wanted.

However, roughly nine out of ten cases are what scientists call dry AMD, which involves progressive degeneration of the macula simply due to the inability of the RPE cells to heal. And while ophthalmologists can identify the disorders onset early on, there are currently no treatments for dry AMD.

Part of the struggle of finding a treatment option is that weve not been able to really model the progression of the disease in cell culture or in animals, said lead author Lindsay Bailey-Steinitz, a doctoral student in the Department of Molecular, Cellular, and Developmental Biology.

Bailey-Steinitz and her collaborators set out with two objectives in mind. The first was to understand what might be going on at the cellular level as the disease progresses. The other was to develop a model that could be used to test therapeutics.

As the RPE cells flounder in their efforts to repair themselves, a hole develops in this layer of the retina that continues to expand. Bailey-Steinitz aimed to recreate this hole in the lab. She cultured RPE cells on a plate with an electrode, then she zapped them. This created a hole very similar to the one that appears in AMD.

However, these were young cells, so they began healing and mending this hole. Thats great for the cells, but not for the team, which was trying to model the disease. So Bailey-Steinitz shocked the cells again. She found that after 10 pulses of electricity over the course of 10 days, the cells were no longer able to effectively repair the damage.

An overview of Coffey and Bailey-Steinitzs experiment.

Photo Credit: LINDSAY BAILEY-STEINITZ

To shed light on how the RPE cells responded to this stress, Bailey-Steinitz sequenced their RNA to figure out what proteins they were synthesizing in their damaged state. She found that some of the most important genes involved in the RPE cells function were suppressed, especially if the cells had been shocked multiple times.

The team also saw changes in gene expression that matched conditions seen in AMD. Whats more, the matrix which provides structural and biochemical support to the RPE cells also changed in ways that resembled the disease pathology.

I wasnt surprised that the RPE profile was down-regulated, Coffey said. If someone gives you a kick, then youre not going to feel well.

But, for that immunology to change and the matrix around the cells as well and to look similar to exactly that profile you see in AMD, I was very surprised.

Now that theyve recreated a similar profile in cultured cells as in the actual disease, the team is progressing to bigger holes, around six millimeters in diameter. Bailey-Steinitz is also planning a similar experiment with older cells, which show a decreased ability to heal.

If we can improve this setup, then weve got a therapeutic testbed for AMD, Coffey said.

Funding for this research came from the William K. Bowes Jr. Foundation, Garland Initiative for Vision, and the California Institute for Regenerative Medicine.

Read the original post:
Seeing Progress - The UCSB Current

ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020, at 11:20 a.m. ET.

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides WCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com

Original post:
CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference - Yahoo Finance

Global Bio-Banks Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ 6.7 Bn by 2026, at CAGR of XX% during forecast period.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/30199

Advancement in biobanking operations in order to ensure optimization of sample storage and maintenance is one of the key factors driving this market. Regenerative medicine through stem cell technology is one of the important treatments for diseases, like Alzheimers, diabetes, cancers, and rare genetic diseases. In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved. With the increase in awareness about stem cell therapies, there has been a larger number of parents who are choosing umbilical cord banks for their children. There are a number of donor banks that are coming up as well. Biobanks not only support in the therapies for genetic diseases but also in medical research on rare genetic disorders. Growing awareness about stem cell therapies and innovation in the field of regenerative medicine are driving the growth of the global biobank market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

Growing in the incidence of chronic diseases, government initiatives, development in drug discovery, and innovation of regenerative medicines, increasing healthcare expenditure and improvement in the treatment of cell and tissue disorders are some of the key factors boosting the global biobanks market. Furthermore, increasing awareness about biobanks is projected to boost the market for biobanks. Rising demographics, economies, and growth in GDP in the emerging countries like India and China, technological advancement and new innovate techniques are expected to offer good opportunities in the global biobanks market. Green banking and virtual biobanks for energy efficiency are some of the key trends that have been observed in global biobanks market. At the same time, expensive techniques, lack of standardization, economic recession and ethical issues related are some of the major factors limiting the growth for global biobanks market.

According to various application, the biobank application is expected to hold a XX% share during the forecast period. On account of different biospecimens stored at biobanks are witnessing significant demand because to advancements in cell-based research activities. Growing demand from different end users has led to the establishment of a substantial number of population-based and disease-based banks in a few years. Population-based banks are established to support precision medicine research initiatives, whereas disease-specific biobanks provide resources to research communities to enable a better understanding of disease etiology.

Among the regions, North America presently leads the global market for biobanks, closely followed by Europe, and it is expected to expand further at the highest CAGR during the forecast period. The increasing demand for Bio-Banks in the U.S. and Canada has allowed the province to have the highest market share. The prominence of these regions on account of the increasing incidence of chronic diseases, the imperative need to find effective treatments for them, large amounts of government investments in the area of biobanks, and the growing number of research activities, together with drug discovery in the region.

The Bio-Banks market report contains in-depth analysis of major drivers, opportunities, challenges, industry trends and their impact on the market. The Bio-Banks market report also provides data about the company and its strategy. This report also provides information on the competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. This research report also adds a snapshot of key competition, market trends during the forecast period, expected growth rates and the primary factors driving and impacting growth market data. This information will be beneficial or helpful to the decision makers.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global Bio-Banks market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global Bio-Banks market.Scope of Global Bio-Banks Market:

Global Bio-Banks Market, ByType:

Optimized Pre-Formulated Media Non-Optimized, Isotonic Formulation MediaGlobal Bio-Banks Market, By Product:

Refrigerators Ice Machines Freezers LN2 Supply Tanks Alarm and Monitoring Systems Cryogenic Storage Systems AccessoriesGlobal Bio-Banks Market, By Application:

Biobanking Regenerative Medicine Drug DiscoveryGlobal Bio-Banks Market, By Analysis:

Human tissue and tumor cells Bio-fluids Stem cells Umbilical cordGlobal Bio-Banks Market, By Region:

North America Europe Asia-Pacific South America Middle East & AfricaKey Players Operated in Market Include:

Home-Brew media solutions Teva Pharmaceuticals Organ Recovery Systems Genzyme Thermofisher Scientific VWR International Beckman Coulter Inc. Taylor-Wharton Tecan AG Panasonic Biomedical Sales Europe B.V. Thermo Fisher Scientific Inc. Taylor-Wharton International LLC So-Low Environmental Equipment Co. BioCision VWR International, LLC Beckman Coulter, Inc. BioLife Solutions, Inc.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/30199

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/30199

MAJOR TOC OF THE REPORT

Chapter One: Bio-Banks Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Bio-Banks Market Competition, by Players

Chapter Four: Global Bio-Banks Market Size by Regions

Chapter Five: North America Bio-Banks Revenue by Countries

Chapter Six: Europe Bio-Banks Revenue by Countries

Chapter Seven: Asia-Pacific Bio-Banks Revenue by Countries

Chapter Eight: South America Bio-Banks Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Bio-Banks by Countries

Chapter Ten: Global Bio-Banks Market Segment by Type

Chapter Eleven: Global Bio-Banks Market Segment by Application

Chapter Twelve: Global Bio-Banks Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Bio-Banks Market Report at:https://www.maximizemarketresearch.com/market-report/global-bio-banks-market/30199/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

More:
Global Bio-Banks Market : Industry Analysis and Forecast (2019-2026) By Type, Product,Application,Analysis,and Region. - Galus Australis

The global Cancer Stem Cells marketis forecast to reach USD 2.18 Billion by 2027, according to a new report by Reports and Data. The market for stem cells for cancer is experiencing increased growth due to the rising number of clinical trials globally. Stem cells are used in regenerative medicine, particularly in the field of dermatology. However, its applications in oncology will witness higher growth rate due to a large number of ongoing pipeline projects for the treatment of cancer or tumors.

The report sheds light on the emerging trends and changes in the market dynamics with regards to the current COVID-19 pandemic. The economic landscape and the market environment have observed drastic changes due to the social restrictions and government-enforced lockdowns imposed to curb the spread of COVID-19. The report is furnished with the latest scenario and growth outlook of the market with regard to the impact of the pandemic. The report covers an extensive impact analysis of the COVID-19 impact on the overall industry and provides a post-COVID-19 perspective of market growth and trends.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3047

The report comprises statistical data neatly organized in the form of graphs, charts, figures, diagrams, and tables to offer a better understanding of the workings of the Cancer Stem Cells industry. The report additionally provides a detailed profiling of the leading market players as well as a regional analysis to understand the landscape and growth curve of the Cancer Stem Cells industry.

The report further provides an extensive report of the key companies and their market share and size in each region. It further talks about the sales network and distribution channels, production, and consumption patterns in each region, and the expected revenue generation and contribution from each segment of the market in each key region.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

AbbVie, Inc., Bionomics, Thermo Fisher Scientific, Inc., Merck KGaA, LONZA, Miltenyi Biotec, Stemline Therapeutics, Inc., PromoCell GmbH, Irvine Scientific, and MacroGenics, Inc., among others.

The Cancer Stem Cells market report provides an estimation of the value of market and market volume. The report further examines and estimates segments and sub-markets in the overall Cancer Stem Cells industry. The report provides an 8-year forecast estimation from 2020 to 2027 inclusive of a range of indices such as supply and demand ratio, production and consumption ratio, market growth, technological innovations, key players of the industry, and product portfolio. It further discusses in detail the revenue estimations, gross margin, sales patterns, and manufacturing cost analysis that will provide a better idea about the global Cancer Stem Cells industry.

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/3047

For the purpose of this report, Reports and Data have segmented the global Cancer Stem Cells market on the basis of treatment type, end-user, disease type, and region:

Treatment Type Outlook (Revenue, USD Billion; 2017-2027)

Disease Type Outlook (Revenue, USD Billion; 2017-2027)

End-User Outlook (Revenue, USD Billion; 2017-2027)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3047

Geographical Analysis of the Cancer Stem Cells Industry:

On the basis of the spread of the Cancer Stem Cells industry in the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The report is analyses the key regions for the production, consumption, revenue, market share, market size, and growth rate of the Cancer Stem Cells industry in these regions for the forecast timeline 2020-2027. The report also provides a country-wise analysis of the Cancer Stem Cells market wherein major countries from the key geographical regions such as the United States, Mexico, Brazil, India, Japan, China, Australia, the U.K, Germany, Saudi Arabia, U.A.E., and other major countries.

In conclusion, the report gives a comprehensive overview of the revenue estimation, market trends, growth factors, and the regional bifurcation of the Cancer Stem Cells industry. It additionally presents SWOT analysis, Porters Five Forces Analysis, Feasibility analysis, and investment return analysis. The report also provides strategic recommendations to the established companies as well as new entrants to assist them in making fruitful business and investment decisions.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/cancer-stem-cells-market

Thank you for reading our report. For further inquiry about customization, kindly get in touch with us and our team will make sure the report is best suited for your needs.

Read more:
Cancer Stem Cells Market Segmentation and Analysis by Recent Trends, Development and Growth by Regions to 2027 | AbbVie, Inc., Bionomics, Thermo...